Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Compass Therapeutics (CMPX) Leases (2022 - 2026)

Compass Therapeutics' Leases history spans 5 years, with the latest figure at $8.7 million for Q1 2026.

  • On a quarterly basis, Leases rose 34.41% to $8.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.7 million, a 34.41% increase, with the full-year FY2025 number at $9.1 million, up 35.18% from a year prior.
  • Leases hit $8.7 million in Q1 2026 for Compass Therapeutics, down from $9.1 million in the prior quarter.
  • Over the last five years, Leases for CMPX hit a ceiling of $9.8 million in Q2 2025 and a floor of $1.2 million in Q2 2024.
  • Historically, Leases has averaged $5.1 million across 5 years, with a median of $4.7 million in 2022.
  • Biggest five-year swings in Leases: crashed 51.66% in 2024 and later surged 750.3% in 2025.
  • Tracing CMPX's Leases over 5 years: stood at $3.0 million in 2022, then tumbled by 40.14% to $1.8 million in 2023, then surged by 279.0% to $6.7 million in 2024, then soared by 35.18% to $9.1 million in 2025, then decreased by 3.88% to $8.7 million in 2026.
  • Business Quant data shows Leases for CMPX at $8.7 million in Q1 2026, $9.1 million in Q4 2025, and $9.5 million in Q3 2025.